copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R R mIDH1 AML in the Journal of Hematology Oncology Nov 12, 2025 8:05am EST
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
Who We Are :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Management Team :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Provides Business Update and 2025 Outlook Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)
Products :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases